Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene Primed For Growth Through 2017, Hugin Says At JPM

This article was originally published in The Pink Sheet Daily

Executive Summary

Celgene CEO Bob Hugin gave investors a taste of what’s to come for the biotech as it prepares for multiple NDA filings this year and the influx of data on several new indications for its lead drugs.

You may also be interested in...

Abraxane Lung Cancer Approval Comes With Questionable Commercial Value

FDA clears Celgene’s Abraxane in lung cancer despite its lack of even a progression-free survival benefit. But the ease of approval is reassurance ahead of the release of melanoma results, with a PFS benefit, in November.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Zafgen Drops Beloranib, But Its New Focus Raises Doubts

The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts